SCHEMBL12427422

SCHEMBL12427422

COc1cc(C(=O)NCCCN2CCCC2)ccc1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.66
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
HTR4 Q13639 3/20 0.64
ATM Q13315 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.59
F10 P00742 1/20 0.58
MAPT P10636 1/20 0.56
HTR1A P08908 1/20 0.55
ADRA2A P08913 1/20 0.55
POLB P06746 1/20 0.55
KMT2A Q03164 3/20 0.55
DRD2 P14416 1/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
PLD2 O14939 1/20 0.54
PLD1 Q13393 1/20 0.54
TLR9 Q9NR96 1/20 0.54
TLR8 Q9NR97 1/20 0.54
TLR7 Q9NYK1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426657 0.99 SLC29A1 (0.65) SLC29A1CYP2D6CYP2C9HTR4ATM
SCHEMBL3542972 0.93 SMN1; SMN2 (0.68) SLC29A1CYP2D6CYP2C9HTR4SMN1; SMN2
SCHEMBL12427360 0.92 CYP2D6 (0.64) SLC29A1CYP2D6CYP2C9HTR4SMN1; SMN2
SCHEMBL13575582 0.92 SMN1; SMN2 (0.67) SLC29A1CYP2D6CYP2C9HTR4ATM
SCHEMBL12427425 0.91 CYP2D6 (0.63) SLC29A1CYP2D6CYP2C9HTR4ATM
SCHEMBL13575609 0.91 CYP2D6 (0.63) SLC29A1CYP2D6CYP2C9HTR4ATM
SCHEMBL13175532 0.91 SMN1; SMN2 (0.65) SLC29A1CYP2D6CYP2C9HTR4SMN1; SMN2
SCHEMBL12426322 0.90 CYP2C9 (0.82) SLC29A1CYP2D6CYP2C9HTR4SMN1; SMN2
SCHEMBL12426329 0.89 HTR4 (0.68) SLC29A1CYP2D6CYP2C9HTR4ATM
SCHEMBL12426361 0.85 KMT2A (0.65) SLC29A1CYP2D6CYP2C9HTR4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003785-B2 Halo-substituted pyrimidodiazepines TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2011-08-23 US disclosed
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 SLC29A1 1367/4885CYP2D6 2081/4885CYP2C9 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.